Recombinant Human LARP1 Protein: Handling & Usage Protocol

Recombinant Human LARP1 Protein is a eukaryotic RNA-binding protein involved in mTORC1-dependent translational regulation and mRNA stability that requires careful reconstitution and storage to maintain full biological activity in downstream assays.

Protein Name

Recombinant Human LARP1 Protein

SKU

rp372330

Protein Family

La-related protein (LARP) family, RNA-binding protein

Primary Function

mTORC1-dependent regulation of mRNA translation and stability, particularly of TOP mRNAs

Recommended Storage

-80°C for long-term storage; avoid repeated freeze-thaw cycles

Recommended Application

RNA pull-down, protein-RNA interaction assays, Western blot, mTOR pathway studies

Background: LARP1 Biology and Research Relevance

LARP1 (La-Related Protein 1) is a member of the La-related protein superfamily and functions as a central effector downstream of the mechanistic target of rapamycin complex 1 (mTORC1). It binds selectively to terminal oligopyrimidine (TOP) motif-containing mRNAs, a class of transcripts encoding ribosomal proteins and translation factors, thereby coupling nutrient-sensing signals to protein synthesis capacity.

Under nutrient-replete conditions, mTORC1 phosphorylates LARP1, modulating its affinity for TOP mRNAs and promoting their translation. Under nutrient stress, LARP1 stabilizes or represses TOP mRNA translation depending on cellular context. LARP1 has been implicated in cancer cell proliferation, viral replication, and cellular stress responses, making it an important research target in oncology, virology, and translational biology.

Recombinant Human LARP1 Protein (SKU: rp372330) enables in vitro biochemical characterization of LARP1 function, including RNA-binding affinity measurements, interaction studies with mTOR pathway components, and substrate competition assays.

Reconstitution and Storage Protocol

Materials Required: Sterile ultrapure water or reconstitution buffer as specified on the product datasheet, low-binding microcentrifuge tubes, ice or cooling block, pipettes with low-retention tips.

Reconstitution Steps:

1. Allow the lyophilized protein vial to equilibrate to room temperature for 10–15 minutes before opening to prevent moisture condensation.
2. Briefly centrifuge the sealed vial (1,000 × g, 30 seconds) to consolidate the lyophilized material at the bottom.
3. Reconstitute in sterile ultrapure water or the buffer recommended on the product-specific datasheet (typically PBS pH 7.4 with a carrier protein such as 0.1% BSA is used to enhance stability). Add the reconstitution volume slowly along the vial wall; do not pipette directly onto the lyophilized cake.
4. Gently swirl or rotate the vial for 2–3 minutes. Do NOT vortex, as shear forces can denature the protein.
5. Allow the solution to stand on ice for 5 minutes to ensure complete solubilization.
6. Briefly centrifuge (10,000 × g, 1 minute, 4°C) to remove any insoluble particulates before use.

Storage Recommendations:

• Short-term (up to 1 week): Store at 4°C.
• Long-term: Aliquot into single-use volumes and store at −80°C. Aliquoting prevents activity loss from repeated freeze-thaw cycles.
• Avoid storing in frost-free freezers that cycle temperatures.
• Record the date of reconstitution on each aliquot.

Note: Specific reconstitution volumes, buffer composition, and concentration values must be confirmed from the product datasheet supplied with SKU rp372330, as formulation details are product-lot-specific.

Quality Verification Before Use

Before initiating downstream experiments, it is best practice to verify protein integrity and concentration. The following checks are recommended:

1. SDS-PAGE / Coomassie Staining: Run a small aliquot (1–2 µg) under reducing and non-reducing conditions on an appropriate percentage polyacrylamide gel. The band should appear at the expected molecular weight for LARP1 (approximately 123 kDa for full-length human LARP1; confirm exact expected MW from the product datasheet for the specific construct used in rp372330). A single predominant band indicates high purity.

2. Western Blot Confirmation: Use an anti-LARP1 antibody to confirm identity. This step is especially important when the protein will be used as a standard or in functional assays.

3. Protein Concentration Measurement: Determine concentration by UV absorbance (A280) using the theoretical extinction coefficient, or by a colorimetric assay (BCA or Bradford). Use a BSA standard curve appropriate for the buffer used. If BSA is present in the reconstitution buffer, account for its contribution to absorbance or colorimetric signal.

4. Endotoxin Testing: For cell-based assays or any application sensitive to lipopolysaccharide (LPS), verify endotoxin levels using a Limulus Amebocyte Lysate (LAL) assay. Endotoxin levels should ideally be below 1.0 EU per µg of protein for cell-culture applications.

Recommended Applications and Working Conditions

Recombinant Human LARP1 Protein (rp372330) is suitable for a range of in vitro biochemical and cell-free applications. The following guidance reflects general best practices for recombinant RNA-binding proteins:

RNA Electrophoretic Mobility Shift Assay (EMSA) / RNA Pull-Down: LARP1 binds TOP motif RNA sequences. For EMSA, titrate LARP1 at a range of concentrations (e.g., 0.1–10 µM) against a fixed concentration of labeled TOP RNA probe in an appropriate binding buffer (e.g., 20 mM HEPES pH 7.5, 150 mM KCl, 2 mM MgCl₂, 0.1 mM ZnCl₂, 1 mM DTT, 0.1 mg/mL BSA, with RNase inhibitor). Incubate on ice for 20–30 minutes before loading on a native gel.

Protein–Protein Interaction (Co-IP / Pull-Down): LARP1 interacts with components of the mTOR pathway, including PABP (poly-A binding protein) and mTOR complex components. Use recombinant LARP1 as bait in pull-down assays with cell lysates or purified interactors.

Western Blot Standard: Use as a positive control or molecular weight standard for anti-LARP1 antibody validation experiments.

Kinase Substrate Assays: LARP1 is phosphorylated by S6K1 (a direct mTORC1 substrate) at multiple sites. Recombinant LARP1 may be used as a substrate in in vitro kinase assays to study mTORC1 pathway activity.

Working Concentration: Optimal concentrations are assay-dependent. Titration experiments are strongly recommended before committing to large-scale experiments. Begin with a concentration range of 0.1–5 µg/mL for most binding and activity assays and adjust empirically.

Avoid: Prolonged incubation at 37°C without protease inhibitors; exposure to detergents above critical micelle concentration; repeated freeze-thaw of working aliquots.

Troubleshooting Common Issues

The table below outlines common issues encountered when working with Recombinant Human LARP1 Protein and suggested corrective actions:

Issue: Protein precipitation or turbidity after reconstitution
Possible Causes: Incorrect reconstitution buffer; too rapid addition of buffer; vortexing.
Solutions: Use recommended buffer from datasheet; add buffer slowly along vial wall; gently swirl rather than vortex; centrifuge at 10,000 × g to remove aggregates; consider adding carrier protein (0.1% BSA).

Issue: No or weak band on SDS-PAGE at expected MW
Possible Causes: Incorrect loading amount; protein degradation; gel percentage inappropriate for ~123 kDa protein.
Solutions: Increase loading amount; use fresh aliquot; use 8–10% polyacrylamide gel for optimal resolution of LARP1; ensure sample buffer contains reducing agent if disulfide-linked aggregates are suspected.

Issue: Loss of RNA-binding activity
Possible Causes: Protein denaturation due to freeze-thaw cycling; RNase contamination in buffers or labware; reducing agent depletion.
Solutions: Use fresh single-use aliquots; treat all buffers and labware with DEPC or use RNase-free certified materials; add fresh DTT or TCEP to binding buffer immediately before use; include RNase inhibitor in binding reactions.

Issue: High background in pull-down assays
Possible Causes: Non-specific binding to resin or probe; insufficient washing stringency.
Solutions: Increase salt concentration in wash buffer (up to 300 mM KCl); include competitor RNA (e.g., yeast tRNA) in binding reaction; optimize blocking conditions with BSA or salmon sperm DNA.

Issue: Inconsistent results between experiments
Possible Causes: Variable protein activity between freeze-thaw cycles; pipetting variability at low concentrations.
Solutions: Prepare single-use aliquots at time of reconstitution; use low-retention tips and tubes; warm aliquot briefly on ice before use; normalize by protein concentration measurement at each use.

Frequently asked questions

What is the recommended reconstitution buffer for Recombinant Human LARP1 Protein (rp372330)?

The reconstitution buffer and volume are specified on the product datasheet supplied with each vial of rp372330. In general for recombinant RNA-binding proteins, sterile PBS (pH 7.4) supplemented with 0.1% BSA is commonly used to maintain solubility and stability. Always defer to the lot-specific datasheet for exact instructions.

How many freeze-thaw cycles can Recombinant Human LARP1 Protein tolerate without significant activity loss?

As a general rule for recombinant proteins, it is recommended to limit freeze-thaw cycles to no more than three. To minimize activity loss, aliquot the reconstituted protein into single-use volumes before storing at −80°C. The specific stability data for rp372330 should be referenced from the product datasheet or confirmed by contacting Aladdin Scientific technical support.

What downstream assays is Recombinant Human LARP1 Protein suitable for?

Recombinant Human LARP1 Protein (rp372330) is suitable for RNA electrophoretic mobility shift assays (EMSA), RNA pull-down assays, protein–protein interaction studies (co-immunoprecipitation and pull-down), in vitro kinase substrate assays (e.g., with S6K1), and Western blot positive controls or antibody validation. Optimal working concentrations should be determined empirically for each assay format.

Why is it important to avoid vortexing when reconstituting LARP1 protein?

Vortexing generates shear forces and air-liquid interfaces that can cause protein unfolding and aggregation, leading to loss of biological activity and increased turbidity. Instead, gently swirl or rotate the vial to dissolve the lyophilized material. This is especially critical for large multi-domain proteins such as LARP1 (~123 kDa), which are more susceptible to mechanical denaturation.

How should I confirm the identity of the LARP1 protein after reconstitution?

Identity can be confirmed by running the protein on SDS-PAGE and checking for a band at the expected molecular weight (approximately 123 kDa for full-length LARP1; confirm from the rp372330 datasheet), followed by Western blot using a validated anti-LARP1 antibody. For high-confidence identification, mass spectrometry analysis can also be used.

References

1. Fonseca BD, et al. La-related protein 1 (LARP1) represses terminal oligopyrimidine (TOP) mRNA translation downstream of mTOR complex 1 (mTORC1). J Biol Chem. 2015;290(26):15996-16020. doi:10.1074/jbc.M114.621730
2. Hong S, et al. LARP1 functions as a molecular switch for mTORC1-mediated translation of an essential class of mRNAs. eLife. 2017;6:e25237. doi:10.7554/eLife.25237
3. Philippe L, et al. The LARP1 La-module recognizes both ends of TOP mRNAs to prevent deadenylation. Nucleic Acids Res. 2018;46(16):8409-8425. doi:10.1093/nar/gky566

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.